Trends in Pharmacological Sciences
Adaptation to myocardial stress in disease states: is preconditioning a healthy heart phenomenon?
Section snippets
Interactions between hypercholesterolaemia and atherosclerosis and preconditioning
Hyperlipidaemia, atherosclerosis and their major clinical sequel, ischaemic heart disease, constitute the leading cause of death in industrialized societies. Moreover, several studies suggest that patients with coronary artery disease who experience frequent ischaemic episodes related to either exercise[9] or mental stress[10] have a worse prognosis than those without such episodes. On the other hand, in clinical practice, the terms `warm-up angina' or `walk-through angina' have been used to
Preconditioning and nitrate therapy
Organic nitrates have constituted the main therapy for angina pectoris for more than a century. One of the fascinating aspects of the pharmacology of nitrates, especially in the context of endogenous cardioprotection, is that these agents for the most part elicit their cardiovascular effects by releasing NO ([29]). Because NO might be a key trigger and/or mediator of ischaemic preconditioning, nitrate therapy is a plausible means of pharmacologically exploiting ischaemic preconditioning[2].
Preconditioning in diabetes
Epidemiological studies have clearly shown that patients with either insulin-dependent diabetes mellitus (IDDM) or non-insulin-dependent diabetes mellitus (NIDDM) are more prone to develop myocardial infarction and post-infarction complications than patients without these disorders, independently of whether or not they display coronary atherosclerosis[37]. Although it has been known for a long time that diabetes is a risk factor for ischaemic heart disease, the literature is inconsistent with
Preconditioning in the hypertrophied and failing myocardium
Systemic arterial hypertension is a recognized risk factor for the development of ischaemic heart disease. Long-standing hypertension might also be associated with the development of left ventricular hypertrophy (LVH). Although LVH can be regarded as a structural adaptive response to a sustained overload of pressure, this condition has grave prognostic implications, independent of all other risk factors. Large cohort studies such as the Framingham study show that hypertensives with LVH have a
Preconditioning and aging
The developing heart undergoes a remarkable metabolic transformation as it adjusts to the rise in oxygen content in the environment outside the uterus[68]. Although protection of the immature heart against ischaemia is an important consideration in corrective surgery for congenital heart diseases[69], the susceptibility of the immature heart to ischaemiaāreperfusion under experimental conditions remains a matter of controversy70, 71. There has been very little investigation of preconditioning
Concluding remarks
It seems likely that the development of new therapeutic agents to protect the ischaemic myocardium will continue to be a major area of cardiovascular research. The mechanisms of classical and delayed preconditioning mechanisms might be feasible paradigms for the development of new pharmacological approaches. However, ischaemic heart disease is a clinically heterogeneous condition. The coexistence of other diseases and risk factors, as we have seen in some experimental models, could impair the
Acknowledgements
P.F. thanks the National Scientific Research Fund (OTKA F6396, F19946, D23736), the National Technical Development Committee (OMFB 05201950616), the Ministry of Education (FKFP 1284/1997) and the Hungarian Space Research Office. G.F.B. thanks the British Heart Foundation for a personal fellowship (FS 97/001) and the Hatter Foundation for its continuing generosity.
References (82)
J. Mol. Cell. Cardiol.
(1995)- et al.
Pharmacol. Ther.
(1996) J. Mol. Cell. Cardiol.
(1995)- et al.
J. Am. Coll. Cardiol.
(1994) Am. Heart J.
(1995)- et al.
Am. J. Cardiol.
(1995) J. Mol. Cell. Cardiol.
(1995)J. Mol. Cell. Cardiol.
(1997)J. Am. Coll. Cardiol.
(1996)J. Am. Coll. Cardiol.
(1997)
J. Mol. Cell. Cardiol.
J. Am. Coll. Cardiol.
J. Mol. Cell. Cardiol.
Ann. Thorac. Surg.
Surgery
J. Am. Coll. Cardiol.
Ann. Thorac. Surg.
J. Mol. Cell. Cardiol.
Pharmacol. Ther.
J. Mol. Cell. Cardiol.
Circulation
Cardiovasc. Res.
J. Am. Med. Assoc.
Am. J. Cardiol.
Circulation
Am. J. Physiol.
Br. J. Pharmacol.
Ann. New York Acad. Sci.
Naunyn-Schmiedeberg's Arch. Pharmacol.
Circ. Res.
Circulation
Biochem. Pharmacol.
Science
Br. J. Pharmacol.
Circ. Res.
Circ. Res.
Circulation
Cardiovasc. Res.
J. Cardiovasc. Pharmacol.
Eur. Heart J.
Cited by (104)
Effects of Ischemic Preconditioning on Abdominal Aortic Aneurysm Repair: A Systematic Review and Meta-Analysis
2019, Journal of Surgical ResearchCitation Excerpt :As a result, some key pitfalls in translation need to be addressed in order to move preconditioning research forward. First, experimental models that predated clinical trials did not recognize the existence of comorbidities such as diabetes and advanced aged, which are known to raise the threshold for preconditioning.43-45 Second, it is plausible that endogenous preconditioning is already present in many of these patients because of existing coronary or peripheral vascular disease (i.e., claudication, angina pectoris, silent ischemia).
Ischemic preconditioning: Interruption of various disorders
2017, Journal of the Saudi Heart AssociationRole of atrial natriuretic peptide in ischemic preconditioning-induced cardioprotection in the diabetic rat heart
2016, Journal of Surgical ResearchRemote ischemic conditioning
2015, Journal of the American College of CardiologyCitation Excerpt :Specific sulfonylureas used to treat type 2 diabetes can attenuate the conditioning response (134). Conversely, insulin, metformin, some statins, angiotensin-converting enzyme inhibitors, antiplatelet agents, and opioids can themselves be cardioprotective and raise the threshold for an additional benefit (64,173,179ā181). A number of pharmacological agents used during cardiopulmonary bypass surgery interfere with the cardioprotective efficacy of RIC.
Role of caveolin-eNOS platform and mitochondrial ATP-sensitive potassium channel in abrogated cardioprotective effect of ischemic preconditioning in postmenopausal women
2022, Brazilian Journal of Pharmaceutical Sciences